TLDR
- President Trump signed an executive order directing health regulators to fast-track the review of psychedelic drugs, triggering a broad sector rally.
- ENVB surged more than 160% in trading, making it one of the biggest movers in the psychedelic biotech space.
- Trump also committed $50 million to ibogaine research, a Schedule I compound being studied for PTSD treatment.
- Compass Pathways (CMPS) rose 26.1%, AtaiBeckley (ATAI) gained 28.1%, and GH Research (GHRS) climbed nearly 20%.
- RBC analyst Brian Abrahams called the executive order “a substantial step towards diminishing regulatory risk” for the sector.
Psychedelic biotech stocks got a jolt Monday after President Trump signed an executive order over the weekend instructing federal health regulators to speed up the review process for psychedelic-based treatments. Enveric Biosciences (ENVB) led the charge, finishing the session up more than 160% — a jaw-dropping move for a stock with a market cap of just $3.43 million.
Enveric Biosciences, Inc., ENVB
The executive order didn’t single out any one company. It was a broad directive to the FDA and related agencies to cut red tape around psychedelic drug approvals. That was enough to send nearly every name in the space flying.
AtaiBeckley (ATAI) jumped 28.1% in premarket. Compass Pathways (CMPS) added 26.1%. Definium Therapeutics (DFTX) gained 14.6%. GH Research (GHRS) was up 19.7%. The rally spread wide and fast.
Trump’s $50M Ibogaine Push
Beyond the executive order, Trump pledged $50 million toward ibogaine research. Ibogaine is a psychoactive compound derived from an African plant and currently sits on the Schedule I list in the U.S. — meaning it has no federally recognized medical use.
The investment signals a real shift in how the administration is thinking about mental health, particularly post-traumatic stress disorder. Ibogaine has shown promise in early research for PTSD, especially among veterans.
Compass CEO Kabir Nath welcomed the executive order publicly, saying it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” RBC analyst Brian Abrahams echoed that view, describing the order as “a substantial step towards diminishing regulatory risk” for psychedelic therapeutics.
ENVB’s rally came with added context. Just days earlier, the company closed a $5 million private placement — a raise that was more than the company’s entire market cap at the time. It sold 2,222,223 shares at $2.25 each, along with two series of warrants priced at $2.00 per share.
ENVB’s Pipeline and IP Moves
The company’s lead drug candidate, EB-003, targets 5-HT2A and 5-HT1B receptors and is being developed for psychiatric and neurological conditions. New mechanistic data released recently showed EB-003 activates dual signaling pathways linked to antidepressant and anxiolytic effects.
ENVB also recently received a U.S. patent covering its EVM301 molecules, which include EB-003, along with Canadian trademark registrations for five of its marks including “Enveric” and “Next Generation Mental Health.”
If both warrant series from the private placement are fully exercised, the company could bring in an additional $8.9 million in gross proceeds.
The stock’s move Monday — over 160% — reflected both the macro tailwind from the executive order and the recent fundraising that gave the company a longer runway heading into that moment.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
